-
Case Report
-
Korean J Med. 2014;87(4):501-504. Published online October 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.87.4.501
- Sunitinib 치료 중인 전이성 신세포암 환자에서 발생한 저혈당성 혼수
-
조미영1, 심혁2, 박무림2
-
1군산의료원 내과
2원광대학교 의과대학 내과학교실
- Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
-
Meyoung Cho1, Hyeok Shim2, Moo-Rim Park2
-
1Department of Internal Medicine, Gunsan Medical Center, Gunsan, Korea
2Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea
- Corresponding author: Hyeok Shim ,Tel: +82-63-859-2642, Fax: +82-63-855-202, Email: mdshim@wku.ac.kr
- Received: January 27, 2014; Revised: March 10, 2014 Accepted: March 28, 2014.
-
߽ɾ :Sunitinib; 저혈당; 대사성 뇌병증
- Abstract
- We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia and metabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renal cell carcinoma. Sunitinib-induced hypoglycemia has been reported and there are rare case reports of severe hypoglycemia due to sunitinib. Therefore, glycemic control should be monitored closely in diabetic patients treated with sunitinib.
Keywords :Sunitinib, Hypoglycemia, Metabolic encephalopathy
